Zymeworks, Inc. (ZYME)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$28.61-0.35%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put ZYME beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Reduce operating expenses by 20% in 2026: Direct metric needs a verified mapping.
View ThesisRevenue is contracting — down about 70% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens weak on earnings delivery, the balance sheet.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationModerate volatility — typically moves about 2% a day.
View RiskZYME depends on Theravance integration to build a diversified, revenue-generating biotechnology business. Its latest reported quarter showed revenue down 90.6% year over year and an earnings miss. ZYME trades at 56× sales versus 10× for peers and 48× historically. The market prices in more growth than our forecast, leaving expectations full. Our model puts the next-quarter miss probability near 65%. The 56× multiple must be earned against that peer gap. Peer multiples imply a price about 4% below where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-30. ZYME is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering ZYME (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for ZYME in the last 4 months.
Continue this research
Compare ZYME with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ZYME Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put ZYME next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Build a diversified, revenue-generating biotechnology business
New Phase 1 data supports pipeline diversification and progress toward a revenue-generating business.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $28.61
The last 12 months of price, then the range of analyst 12-month targets from today’s $28.61.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Build a diversified, revenue-generating biotechnology business
New Phase 1 data supports pipeline diversification and progress toward a revenue-generating business.
Advances: Build a diversified, revenue-generating biotechnology business
ZW191 trial results advance pipeline diversification, though zanidatamab remains the central tracked catalyst.
Advances: Build a diversified, revenue-generating biotechnology business
Roche licensing deal adds partnered-product potential and diversifies revenue, though payments are contingent.
Advances: Complete acquisition of Theravance Biopharma and integrate assets
Analyst upgrade supports acquisition strategy and market confidence.
Advances: Complete acquisition of Theravance Biopharma and integrate assets
Merger approval supports acquisition and integration objectives.
Advances: Complete acquisition of Theravance Biopharma and integrate assets
The acquisition enhances cash flow and asset integration.
Advances: Advance zanidatamab regulatory approvals and milestone realization
Analyst upgrade reflects confidence in regulatory approval progress.
